申请人:[en]DIALECTIC THERAPEUTICS, INC.
公开号:WO2022103881A1
公开(公告)日:2022-05-19
A pharmaceutically nanoemulsion formulation of Compound 1 is disclosed along with methods for making the same. An example embodiment of the nanoemulsion of Compound 1 is comprised of lecithin, medium chain triglycerides (MCT), sucrose, EDTA and water.